Brain Network Changes and Fluoxetine Treatment for OCD
This study is looking at how the brain changes in people with Obsessive-Compulsive Disorder (OCD) when they are treated with fluoxetine, a common medication. Researchers want to understand what brain changes happen during treatment and if these changes can predict who will respond well to fluoxetine. You might be eligible if you are an adult between 18 and 65 years old with OCD. The study will measure changes in your OCD symptoms over 18 weeks to see if the treatment is successful. The current status of this study is unclear, and it aims to enroll 100 participants.
- Study design
- This is a randomized, double-blind study. Participants with OCD will either receive fluoxetine immediately or after a 6-week placebo period.
- What's involved
- Participants will have fMRI scans at the beginning and during treatment. Some participants will receive fluoxetine, while others will have a 6-week placebo lead-in.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint for measuring obsessive-compulsive severity change is at 18 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Christopher Pittenger, MD, PhD · PRINCIPAL_INVESTIGATOR · Professor of Psychiatry; Director, Yale OCD Research Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Obsessive-compulsive severity change18 weeks
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS);72,73 -This is a checklist and Clinician administered - 10 item severity scale, from none to extreme. Total severity score range is 0 to 40. This will be presented as % improvement in Y-BOCS as a continuous measure of treatment response, rather than an artificially dichotomized measure of 'response', in all analyses. This the primary outcome measure of change across the study treatment and scans.